Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech - Technical Analysis -- Ignore unavailable to you. Want to Upgrade?

To: rolatzi who wrote (198)	3/19/2002 9:35:31 PM
From: JEB	Respond to of 544

Study Shows New Data Supporting ZADAXIN's Ability to Increase Th1 Subset Of T-Helper Cells Data Presented at World Congress of Gastroenterology SAN MATEO, Calif., Mar 19, 2002 /PRNewswire-FirstCall via COMTEX/ -- SciClone Pharmaceuticals (Nasdaq: SCLN chart, msgs) today announced the results of a nonclinical study supporting ZADAXIN's observed mechanism of action. The study was presented this month at the World Congress of Gastroenterology in Bangkok, Thailand. The results indicate that ZADAXIN promotes an anti-viral immune system response by increasing the Th1 subset of helper T cells, the natural killer cells and cytotoxic CD8 T cells. This new study was conducted on liver-infiltrating T cells from biopsies taken from patients with chronic hepatitis B enrolled in SciClone's phase 3 clinical trial in Japan. Both an increase in the number of Th1 cells and, importantly, a decrease in the number of Th2 cells were observed in the liver of these patients. This combined effect is thought to be critical in fighting chronic viral infection and cancer. Prior reported studies examined increases in T cell levels circulating in the peripheral blood "We are pleased to see additional independent research supporting ZADAXIN's proposed mechanism of action.," commented Alfred Rudolph, MD, SciClone's Chief Operating Officer. "This study shows that ZADAXIN enhances the patient's immune system by stimulating the Th1 response required to eliminate the hepatitis B virus where it is critical to do so, within the liver." ZADAXIN has been administered without side effects to over 10,000 patients and is approved for sale in 26 countries, principally for the treatment of hepatitis B and hepatitis C, and certain cancers. ZADAXIN, an immune system enhancer (ISE), is a synthetic preparation of thymosin alpha 1, an immune system peptide that exists naturally in humans and whose activities are recognized to regulate the body's effective immune response to serious viral infections and certain cancers. siliconinvestor.com